Prostate cancer remains one of the most common cancers among men.
As treatment options expand, so do the challenges of allocating healthcare resources effectively.

Amid increasing budget constraints, health economic models have become essential tools for evidence-based decision-making.

We’re pleased to share a recently published systematic literature review on economic evaluations and modeling approaches in the treatment of metastatic castration-sensitive prostate cancer (mCSPC).

This study is the result of a collaborative effort by the consortium.

Study Objective

To synthesize available economic evaluations and health economic models used in mCSPC treatment, focusing on Europe and North America.

Key Findings

• The deterministic Markov model (Markov cohort or partitioned survival) was the most commonly used structure.
• Most models simulate patient transitions from castration-sensitive to castration-resistant states, ending with death.
• These findings support rapid, context-appropriate policy decisions and the design of future evaluations.

Read the full article here:

https://www.mdpi.com/1718-7729/32/8/412

DE-ESCALATE is funded by the European Union and is under the legal sponsorship of EORTC – European Organisation for Research and Treatment of Cancer.